HF
CLYM

HRT Financial’s Climb Bio CLYM Stock Holding History

HRT Financial’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,161
Closed -$254K – 5614
2026
Q1 		$254K Buy
+37,161
New +$214K ﹤0.01% 3020
2025
Q3 		– Sell
-18,529
Closed -$22K – 3866
2025
Q2 		$22K Buy
+18,529
New +$23.1K ﹤0.01% 2395
2021
Q4 		– Sell
-11,797
Closed -$212K – 4235
2021
Q3 		$212K Buy
+11,797
New +$244K ﹤0.01% 2646

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HRT Financial's CLYM Position: Q2 2026 in Review

HRT Financial sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 37,161 shares — an estimated $254K sold.

HRT Financial first reported a position in CLYM in Q3 2021 and held it in 3 quarters. The position peaked at $254K in Q1 2026. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • HRT Financial reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 37,161 Climb Bio shares in Q2 2026, an estimated $254K.
  • HRT Financial first reported a position in Climb Bio in Q3 2021 and held it in 3 quarters.
  • HRT Financial's Climb Bio position peaked at $254K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.